GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Parnell Pharmaceuticals Holdings Ltd (OTCPK:PARNF) » Definitions » EPS (Diluted)

Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) EPS (Diluted) : $0.01 (TTM As of Dec. 2018)


View and export this data going back to 2014. Start your Free Trial

What is Parnell Pharmaceuticals Holdings EPS (Diluted)?

Parnell Pharmaceuticals Holdings's Earnings per Share (Diluted) for the six months ended in Dec. 2018 was $0.01. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2018 was $0.01.

Parnell Pharmaceuticals Holdings's EPS (Basic) for the six months ended in Dec. 2018 was $0.01. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2018 was $0.01.

Parnell Pharmaceuticals Holdings's EPS without NRI for the six months ended in Dec. 2018 was $-0.11. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2018 was $-0.11.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Parnell Pharmaceuticals Holdings EPS (Diluted) Historical Data

The historical data trend for Parnell Pharmaceuticals Holdings's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Parnell Pharmaceuticals Holdings EPS (Diluted) Chart

Parnell Pharmaceuticals Holdings Annual Data
Trend Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
EPS (Diluted)
Get a 7-Day Free Trial -2.04 -0.75 -1.01 -0.98 0.01

Parnell Pharmaceuticals Holdings Semi-Annual Data
Jun12 Jun13 Jun14 Dec15 Dec16 Dec17 Dec18
EPS (Diluted) Get a 7-Day Free Trial -2.04 -0.75 -1.01 -0.98 0.01

Competitive Comparison of Parnell Pharmaceuticals Holdings's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Parnell Pharmaceuticals Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Parnell Pharmaceuticals Holdings's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Parnell Pharmaceuticals Holdings's PE Ratio distribution charts can be found below:

* The bar in red indicates where Parnell Pharmaceuticals Holdings's PE Ratio falls into.



Parnell Pharmaceuticals Holdings EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Parnell Pharmaceuticals Holdings's Diluted EPS for the fiscal year that ended in Dec. 2018 is calculated as

Diluted EPS (A: Dec. 2018 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(0.093-0)/18.027
=0.01

Parnell Pharmaceuticals Holdings's Diluted EPS for the quarter that ended in Dec. 2018 is calculated as

Diluted EPS (Q: Dec. 2018 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(0.093-0)/18.027
=0.01

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2018 was $0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Parnell Pharmaceuticals Holdings  (OTCPK:PARNF) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Parnell Pharmaceuticals Holdings EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Parnell Pharmaceuticals Holdings's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Parnell Pharmaceuticals Holdings (Parnell Pharmaceuticals Holdings) Business Description

Traded in Other Exchanges
N/A
Address
476 Gardeners Road, Unit 4, Century Estate, Alexandria, Sydney, NSW, AUS, 2015
Parnell Pharmaceuticals Holdings Ltd is an Australia based veterinary pharmaceutical company. It is focused on developing, manufacturing and commercializing animal health solutions. The group manufactures and market products for companion animals and production animals. The firm also has a pipeline of drug products like Zydax, PAR121 and PAR122 and Luminous which covers therapeutic areas in orthopedics, dermatology, and nutraceuticals. The operating segments of the company are Companion animal, Production animal - U.S., Production animal - rest of world and Contract Manufacturing. It operates internationally and generates the majority of the revenue from the Production animal - U.S. segment which covers the group's reproductive hormone portfolio across production animal in the USA.